Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib add-on therapy in mild to moderate Alzheimer's disease
2021-002179-21Phase 3Completed
- Sponsor
- AB Science
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Masitinib add-on to standard of care with Placebo add-on to standard of care (2 arms). Primary endpoints: ADCS-ADL improvement versus placebo and ADAS-Cog improvement versus placebo. Started Mar 2022; status: completed.
02
Drugs
masitinib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2021-002179-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002179-21.